Dexloxiglumidum
Dexloxiglumidum Uses, Dosage, Side Effects, Food Interaction and all others data.
Dexloxiglumidum is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.
Dexloxiglumidum is a selective cholecystokinin type A (CCKA) receptor antagonist. In October 2003, following the completion of two phase III clinical studies involving dexloxiglumide in women with constipation-predominant irritable bowel syndrome (IBS), Forest Laboratories decided to discontinue development of the drug for this indication. The results of the studies showed that dexloxiglumide did not show statistically significant favorability over placebo. Rotta Research is continuing a phase III trial of a different design in Europe for the IBS indication and also for gastroesophogeal reflux disease.
| Trade Name | Dexloxiglumidum |
| Generic | Dexloxiglumide |
| Dexloxiglumide Other Names | Dexloxiglumida, Dexloxiglumide, Dexloxiglumidum |
| Type | |
| Formula | C21H30Cl2N2O5 |
| Weight | Average: 461.379 Monoisotopic: 460.153177494 |
| Protein binding | 94-98% |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of Irritable Bowel Syndrome (IBS) and Gastroesophageal Reflux Disease (GERD).
How Dexloxiglumidum works
CCKA antagonists target receptors in the gastrointestinal system to increase gastric emptying and intestinal motility, as well as modulate intestinal sensitivity to distension.
Elimination Route
Rapidly and extensively absorbed after single oral administration in humans with an absolute bioavailability of 48%. The incomplete bioavailability is due to both incomplete absorption and hepatic first-pass effect.
Innovators Monograph
You find simplified version here Dexloxiglumidum
